Company profile for MAIA Biotechnology

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

MAIA Biotechnology, Inc. is a targeted therapy, immuno-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. A privately-held company based in Chicago, MAIA is led by a passionate, principled and highly experienced Management Team with significant drug development experience, committed to adv...
MAIA Biotechnology, Inc. is a targeted therapy, immuno-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. A privately-held company based in Chicago, MAIA is led by a passionate, principled and highly experienced Management Team with significant drug development experience, committed to advancing promising agents into clinical trials. MAIA’s business model involves placing drug candidates in their own dedicated, R&D focused subsidiary company, which is supported by the common infrastructure.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
444 West Lake Street Suite 1700 Chicago, IL 60606
Telephone
Telephone
(312) 416-8592
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/16/3206621/0/en/MAIA-Biotechnology-Announces-1-51-Million-Private-Placement.html

GLOBENEWSWIRE
16 Dec 2025

https://www.globenewswire.com/news-release/2025/12/11/3203966/0/en/MAIA-Biotechnology-Announces-First-Patient-Dosed-in-THIO-104-Phase-3-Pivotal-Trial-Evaluating-Ateganosine-as-Third-Line-Treatment-for-Advanced-Non-Small-Cell-Lung-Cancer.html

GLOBENEWSWIRE
11 Dec 2025

https://www.globenewswire.com/news-release/2025/12/11/3203842/0/en/MAIA-Leadership-Continues-Insider-Buying-in-2025-and-Trial-Data-Signals-Breakout-Potential.html

GLOBENEWSWIRE
11 Dec 2025

https://www.globenewswire.com/news-release/2025/12/11/3204217/0/en/MAIA-s-Ateganosine-Surges-Ahead-with-Breakthrough-Momentum-as-Pivotal-Phase-3-Trial-Initiates.html

GLOBENEWSWIRE
11 Dec 2025

https://www.globenewswire.com/news-release/2025/12/10/3203460/0/en/MAIA-Takes-Aim-at-a-50B-Immunotherapy-Market-with-Breakthrough-Telomere-Targeting-Approach.html

GLOBENEWSWIRE
10 Dec 2025

https://www.globenewswire.com/news-release/2025/12/01/3197114/0/en/MAIA-Biotechnology-Announces-Open-Market-Purchases-by-CEO-and-Directors.html

GLOBENEWSWIRE
01 Dec 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty